Fundacion Para La Investigacion Biomedica Hospital Clinico San Carlos
- Address
- lock Available on a paid plan
Neoplasms and Oncology Research
At Fundacion Para La Investigacion Biomedica Hospital Clinico San Carlos, the Medical Oncology program includes clinical research in neoplasms, with a focus on advanced gastrointestinal stromal tumor. These studies are designed to better understand treatment effects and support the development of more effective cancer therapies.
- Evaluation of a new treatment approach for advanced gastrointestinal stromal tumor
- Assessment of how a cancer therapy behaves in the body and its potential impact on care
This line of research reflects the site’s role as a laboratory and research facility contributing to oncology studies in Madrid.
Nervous System Diseases and Alzheimer’s Research
Another major area of activity is nervous system diseases, especially early Alzheimer's disease. The trials here are focused on testing new therapies and measuring whether they can slow clinical decline while supporting cognition and daily function.
- Testing an anti-tau monoclonal antibody for early Alzheimer's disease
- Evaluating changes in cognition and function as part of treatment effectiveness research
These studies aim to improve how Alzheimer’s disease is treated and monitored, with interest in both symptom control and disease progression.
Translational and Immune Response Studies
The site also supports research that helps explain how patients respond to treatment, including work on immune response in participants from a posdinemab study. This type of research is important for refining future therapies and understanding which patients may benefit most.
- Characterizing immune response in participants receiving investigational treatment
- Supporting the development of better diagnostics and treatment evaluation in medical oncology and neuroscience
With a small but focused portfolio of trials, the center combines clinical research expertise with disease-specific investigation across cancer and neurodegenerative conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fundacion Para La Investigacion Biomedica Hospital Clinico San Carlos
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease | Janssen Cilag International | Phase II | Not Recruiting | Apr 2021 | Mar 2026 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 6-(Fluoro-18F)-3-(1H-Pyrrolo[2,3-C]Pyridin-1-Yl)-5-Isoquinolinamine | 1 | Unknown | 2021-04-15 | 2021-04-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.